Method for producing agent possessing anti-ischemic and antioxidant activity

FIELD: pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, particularly to a method for producing the agent, possessing anti-ischemic and antioxidant activity. Disclosed is a method for producing agent possessing anti-ischemic and antioxidant activity, by grinding plant repertory, comprising Membranous Milk Vetch roots, Baikal skullcap roots, Siberian Alexandrian laurel rhizomes and roots, by its three-stage extraction with 60 % ethanol, then, banded aqueous-alcoholic extracts are being filtered, evaporated, purified by separation, finally boiled out, then dried in a vacuum drying apparatus under certain conditions.

EFFECT: agent produced as described above possesses the evident anti-ischemic and antioxidant activity.

1 cl, 10 tbl

 



 

Same patents:

FIELD: transport, distribution.

SUBSTANCE: invention relates to proportioning. Batcher 10 comprises at least one vessel 12 with the bulk M of solid substance 14, at least one feed pipeline 20 connected with said vessel 12 to feed fluid in amount L to said vessel 12. Note here that said portion P of said solid substance is either partially or completely dissolved in said fluid to obtain aforesaid solution. Said portion P is notably smaller than bulk M so that said vessel 12 contains permanently the positive portion of said solid substance. Said positive part is defined by subtracting said P from M. Batcher 10 can comprise outlet pipe 16 for extraction of continuous portions of obtained solution and at least measuring means 22 to track at least one characteristic of the solution part. Invention covers also the methods of solution proportioning.

EFFECT: perfected system, simplified transportation and storage and making of the solution of preset concentration.

34 cl, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to a method for preparing a medicinal product possessing choleretic activity. The medicinal product possessing choleretic activity and prepared by extracting an elevated part of Lomatogonium carinthiacum in 96% ethanol twice at room temperature, them in 40% ethanol with an extractant added in an amount equal to a discharged one, twice; the filtered aqueous-alcoholic extracts are combined; the extraction cake is extracted in purified water; the aqueous extract is filtered; the aqueous residues of the aqueous-alcoholic extracts are combined with the aqueous extract, concentrated, dried in a vacuum drying cabinet to produce the dry extract in the certain environment.

EFFECT: medicinal product prepared as described above possesses the evident choleretic activity.

11 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to method of obtaining 7-hydroxyroyleanon, possessing antimicrobial action. said method includes extraction of crushed roots of salvia officinalis with 96% ethyl alcohol with further extract evaporation, processing with water, alcohol distillation and processing with hydrophobic solvent or extraction of said raw material with chloroform with further extract processing with water and evaporation; after which target product is extracted from organic phase by transfer into water-soluble phenolates, with processing with sodium hydroxide water solution; alkali solution is washed with chloroform; acidified with hydrochloric or sulphuric acid; obtained sediment is filtered; dried and crushed.

EFFECT: invention is characterised by improved process manufacturability and provides obtaining individual substance with higher antimicrobial activity than previously extracted royleanon derivatives from salvia officinalis.

2 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: method includes treating crushed Echinacea purpurea (L.) Moench roots and rhizome with steam, extraction with ethyl alcohol, then steeping, stirring, steeping, draining a portion of the extract which is equal to the amount of the loaded Echinacea purpurea (L.) Moench roots and rhizome, after draining a portion of the extract, adding ethyl alcohol to the treated material, draining the whole extract; extracting crushed Echinacea purpurea (L.) Moench herbs with ethyl alcohol, steeping, then stirring, steeping, draining a portion of the extract which is equal to the amount of the loaded Echinacea purpurea (L.) Moench herbs, after draining a portion of the extract, adding ethyl alcohol to the treated herbs, draining the whole extract; all obtained extracts are mixed, cooled and filtered under certain conditions. An Echinacea purpurea (L.) Moench tincture. Use of the method to obtain an Echinacea purpurea (L.) Moench tincture.

EFFECT: method preserves the biological activity of components of the tincture and medicinal properties.

3 cl

FIELD: chemistry.

SUBSTANCE: invention relates to a method of producing dry propolis. Said method includes grinding raw material, extraction with 96% ethyl alcohol at temperature of +20-25°C using a vacuum-ultrasonic device, filtering, purification from heavy metals and other impurities using a carbon sorbent, followed by evaporation.

EFFECT: disclosed method increases output of biologically active substances and enables purification of propolis from wax, mechanical impurities, high-molecular weight substances, heavy metals and pesticides.

2 dwg, 3 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: means represents a dry extract of leaves and flowers of Gratiola officinalis, obtained by milling the leaves and flowers of Gratiola officinalis, extraction with 96% alcohol on a water bath to boiling and boiling, evaporation, dilution of the evaporated residue first with distilled water, then by the addition of chloroform, cooling to room temperature and centrifuging with the following separation of a water fraction and drying it under specified conditions.

EFFECT: means is non-toxic, has an expressed anti-tuberculosis action.

2 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: method of producing α(1,2)-L-skeleton-α(1,4)-D-galactopyranosyluronan from Acorus calamus L rhizome is carried out in two steps. At the first step, crushed material is extracted with acidified water and heated on a boiling water bath while periodically mixing; after settling, the mixture is heated once more, left to cool to room temperature and filtered through a multilayer fabric filter; the filtrate is evaporated under a vacuum; the obtained solution is slowly added to 96% ethyl alcohol or to a solution of reclaimed ethanol and left in a cool place to settle the residue, after which the settled solution is drained, and the residue is filtered through a paper filter by successively washing with 96% ethyl alcohol and then with acetone. At the second step, without drying, the residue is transferred from the filter and dissolved in purified water while stirring rapidly; the obtained solution is then centrifuged; the obtained solution is purified from low-molecular weight compounds by filtering through a semi-permeable membrane; the purified solution is frozen and freeze-dried at certain conditions.

EFFECT: improved method.

3 dwg, 6 tbl

FIELD: medicine.

SUBSTANCE: method for producing Befungin, a preparation of Chaga mushroom involving extracting the milled raw material in heated water on a heating unit consisting of 3 reactors; adding cobalt salts to the extract in certain environment, mixing with ethanol, evaporating to dry residue of 20-25%.

EFFECT: method enables accelerating the production process, reducing energy demands, improving the quality and completeness of extraction, and improving the quality of the preparation.

2 dwg, 1 tbl, 1 ex

FIELD: aviation.

SUBSTANCE: invention represents the method to obtain the soluble concentrate from sideline products of reindeer antlers, comprising aqueous raw extraction, grounded up to the forced meat condition with particle size of 3-5 mm under the action of ultrasonic vibrations with frequency of 37 kHz with subsequent filtration and vacuum drying at temperature of 45°C and pressure of 0.9 atm, distinguished by the fact that the aqueous raw extraction is carried out at temperature of 35-36°C in the presence of pepsin ferment at its concentration in raw mixture: water of 0.5% during at least 3 hours, at ratio raw: water for tails 1:5, for male genital 1:4, for uteruses with embryos and amniotic fluid 1:2.

EFFECT: significant increase of final concentrate yield from sideline products of reindeer antlers.

3 ex, 2 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to method of simultaneous obtaining of two flavonoids - patuletine and its 7-O-β-D-glucopyranoside - patuletrine. Method consists in the following: milled edge petals of flower of high flavonoid sorts of tagetes patula are extracted with hexane, dried and r-extracted with chloroform, chloroform extract is concentrated, dry residue is dissolved in mixture of petroleum ether - chloroform, precipitated sediment is filtered, washed with petroleum ether and dried, obtained dry powder is dissolved in mixture chloroform - ethanol, precipitated sediment is filtered, washed with petroleum ether and dried with obtaining patuletine. Then, extraction of raw material, which remains after chloroform processing, is carried out with ethanol, alcohol extract is filtered and concentrated, after that, water residue is subjected to liquid phase extraction with ethylacetate, then, organic layer is concentrated, dry residue is dissolved in mixture chloroform - ethylacetate, precipitated sediment is filtered, washed with cooled ethylacetate, solution of hydrochloric acid in ethanol, ethanol and ethylacetate and dried, dry powder is dissolved in mixture ethylacetate-ethanol, precipitated sediment is filtered, washed with ethylacetate and dried with obtaining patuletrine.

EFFECT: method makes it possible to obtain highly pure samples of patuletine and patuletrine, as well as increase target product output.

4 dwg, 3 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to cardiovascular surgery and cardiology, and deals with complex correction of immunoinflammatory responses of cardiovascular bed. For this purpose, in case of presence of high level of circulating immune complexes and/or complement in patient, three sessions of plasmapheresis in accordance with conventional methods, and in case of low level of IgG and reduced phagocytic activity of neutrophils and monocytes, as well as in case of confirmed autoimmune process, a course of intravenous infusions of human polyvalent immunoglobulin is carried out in accordance with conventional schemes.

EFFECT: method provides reduction of both hypo- and hyperactive disorders in immune system of patients and resulting increase of efficiency of treatment of cardiovascular system diseases.

3 ex

FIELD: medicine.

SUBSTANCE: limb ischemia is simulated in a male Wistar rat anaesthetised with chloral hydrate in a dose of 250-300 mg/kg by the surgical removal of femoral, popliteal arteries and the front shin artery. That is followed by introducing a prepared mononuclear fraction of the autologous bone marrow in a dose of 4×106 cells in an amount of 200 mcl. The above is introduced into the ischemic limb from two points in an amount of 100 mcl each. One point is found directly under the femoral arch paravasally within the anatomical position of collaterals of the inner iliac artery and its branches. The other point is located in the calf muscle on an anteriolateral surface of the midleg.

EFFECT: more effective experimental treatment ensured by stimulating the collateral blood flow in the ischemic limb and improving the arterial blood flow from the proximal to distal parts of the limb.

1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: early postoperative period involves administering low-molecular heparins and anti-inflammatory agents. Anti-inflammatory therapy requires administering cycloferon according to the schedule: 2 tablets of cycloferon 0.15 mg on the first preoperative day, 2 tablets on the first postoperative day, 2 tablets in the morning on the 2nd, 4th, 6th postoperative day, and further, every third day throughout 1 postoperative month (on the 9th, 12th, 15th, 18th, 21st, 24th, 27th, 30th day).

EFFECT: method provides the effective prevention of postpericardiotomy syndrome with a lower risk of side effects by administering cycloferon according to the developed schedule requiring non-steroidal anti-inflammatory agents and glucocorticosteroids.

2 ex, 3 tbl

Treatment // 2554801

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, and concerns using a human Annexin-1 antibody (Anx-A1), which has the sequence SEQ ID NO: 23 for treating a disease caused by abnormal T-cell activation. The group of inventions also concerns a method of treating a disease caused by abnormal T-cell activation, involving administering a therapeutic amount of the above antibody into an individual in need thereof; using the above antibody for producing a therapeutic agent for treating a disease caused by abnormal T-cell activation.

EFFECT: group of inventions provides treating the disease caused by abnormal T-cell activation.

9 cl, 11 ex, 22 dwg

FIELD: medicine.

SUBSTANCE: invention concerns rehabilitation of elderly patients with ischemic heart disease (IHD) accompanied by chronic heart insufficiency (CHI) following myocardial in myocardial infarction (MI). That is ensured by administering Omacor, a preparation of omega-3-polyunsaturated fatty acids in the remote period, 6 or more months after the suffered MI with underlying a standard drug therapy 60 minutes before the graduated walking.

EFFECT: this complex of the drug preparations combined with the graduated physical exercises provides higher tolerance to physical exercises, improving the cardiovascular function and normalising the lipid exchange that in turn leads to reducing a number of unfavourable cardiovascular episodes and delaying CHI.

2 ex, 5 tbl

FIELD: medicine.

SUBSTANCE: claimed is the application of N-(2-adamantyl)-hexamethylenimine hydrochloride (himantane) as a medication for treating cerebral circulation disorders and brain traumas. An ability of himantane to reduce animal morbidity and increase cognitive and motor indices in case of its introduction after 3.5 hours after modelling a hematoma in rats and further introduction for 4 days was determined, which testifies to its possessing the neuroprotective potential on the model of the intracerebral post-traumatic hematoma. The technical result consists in the realisation of the claimed purpose: it has been shown that himantane in a dose of 5 mg/kg in case of intravenous introduction causes the increase of cerebral circulation in the rats' brain after ischemic brain affection without changing the level of arterial pressure.

EFFECT: medication did not produce a significant impact on the blood supply of the brain of the intact animals and did not cause a change in the heart rate and respiratory rate.

1 dwg, 6 tbl

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine, namely to neurology, and deals with the treatment of ischemic stroke. For this purpose the introduction of ubidecarenone by injection, mainly intravenous, is carried out.

EFFECT: introduction of the medication provides the reduction of the zone of brain tissue injury and reduction of neurologic deficiency expression due to the accumulation of ubidecarenone, possessing an expressed neuroprotective action, in brain tissues.

7 cl, 4 dwg, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a compound of formula , which is a methylhydrofumarate (MHF) prodrug. In formula (I), radicals and symbols have the values specified in the patent claim. The invention also refers to a pharmaceutical composition containing the declared methylhydrofumarate drugs, to using the declared methylhydrofumarate drugs and the pharmaceutical composition containing them, for treating diseases, such as psoriasis, asthma, multiple sclerosis, inflammatory intestinal disease and arthritis, and to a method of treating the above diseases.

EFFECT: higher oral bioavailability and plasma MHF, dimethylfumarate and/or other metabolites.

47 cl, 1 tbl, 54 ex

FIELD: medicine.

SUBSTANCE: antianginal therapy is accompanied by a primary discrete plasmapheresis in a refrigerate centrifuge PC-6 having a rotating speed of 2,000 rpm for 15 minutes at a temperature of 22°C in number of 5 sessions every second day. One session involves removing the whole blood in an amount of: 2 flexible PVC packages x 450 ml if the patient's body weight index is from 18 to 29.9 kg/m2, 3 flexible PVC packages x 450 ml if the patient's body weight index is over 30 kg/m2. The total volume of the removed plasma makes 600-900 ml. The circulating blood volume is replaced with 0.9% NaCl in an amount of half as much as the removed plasma volume. Once the plasmapheresis course is completed, the blood is exposed to ultraviolet light generated by OVK-3 apparatus for at wave length more than 400 nm in number of 5 procedures every second day.

EFFECT: effective treatment of the given category of the patients by improving the haemorheology, normalising the lipid spectrum without increasing liver enzymes with preserving the hepatic function, decreasing the dyslipidemia level and functional class of angina in the patients with limited use of statins with underlying cholestasis.

2 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: urgent surgery on vessels of a lower extremity involves placing an electrode for transoesophageal atrial temporal pacing (TOTP). That is followed by administering a beta adrenergic blocking agent intravenously in a load dose to achieve a decreased heart rate of ≤ 60 beats per minute. The dose of the beta adrenergic blocking agent is reduced to a maintaining one with preserving a sinus decreased heart rate from 72 to 74 beats per minute for the whole surgery and for 2-3 days thereafter as it may be necessary. The surgical repair of coronary arteries is performed at least 3-4 weeks after the surgery on the vessels of the lower extremities.

EFFECT: therapeutic approach provides preventing minor cardiac output syndrome and other cardiovascular adverse effects accompanying the repair surgeries on the arteries of the lower extremities that enables a coronary artery bypass surgery 3-4 weeks later.

2 cl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to selenium nanocomposites of natural hepatotrophic galactose-containing polysaccharide matrixes, representing water-soluble orange-red powders containing zerovalent selenium (Se0) nanoparticles sized 1-100 nm in the quantitative content of 0.5 - 60 wt %, possessing antioxidant activity for treating and preventing redox-related pathologies, particularly for treating toxic liver damage, to a method for producing and to an antioxidant agent containing the above nanocomposites.

EFFECT: invention provides the targeted agent delivery to liver cells, as well as higher agent accessibility and lower toxic action of selenium.

7 cl, 11 ex, 4 tbl

Up!